FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308376056> ?p ?o ?g. }

• W4308376056 abstract "<h3>Background</h3> Chimeric antigen receptor (CAR) T cell therapies have demonstrated limited efficacy against solid tumors, in part due to challenges overcoming solid tumor heterogeneity and CAR T cell exhaustion associated with the immunosuppressive tumor microenvironment (TME). Our integrated platform aims to overcome these roadblocks by engineering T cells in vivo to express a universal TagCAR which binds to a common tag on bispecific adaptor TumorTags, bridging TagCAR T cells to TumorTag-bound tumor- and TME-associated antigens, including folate receptor (FR) which is upregulated on many tumor types as well as immunosuppressive tumor-associated macrophages. Additionally, our TagCAR T cells are engineered to express a rapamycin-activated cytokine receptor (RACR) which selectively provides survival signals to TagCAR T cells in the presence of rapamycin. Here, we identify a universal TagCAR that demonstrates potent in vitro and in vivo anti-tumor polyfunctionality against FR⁺ target cells with a folate receptor-targeting TumorTag (UB-TT170). <h3>Methods</h3> PBMCs from healthy donors were transduced in vitro with surface-engineered lentiviral vectors with TagCAR/RACR payloads. Resultant TagCAR T cell anti-tumor activity and persistence was assessed using a co-culture approach with FR-expressing tumor cells and titrated doses of UB-TT170. To assess in vivo anti-tumor activity, lentiviral particles containing TagCAR/RACR payloads were administered to PBMC-humanized NSG mice with established FR⁺ xenograft solid tumors to generate TagCAR T cells in vivo. Mice were treated with UB-TT170 and efficacy was determined by assessing tumor regression and UB-TT170-mediated TagCAR T cell expansion. <h3>Results</h3> TagCAR T cells containing a CD8α hinge/transmembrane domain and 41bbζ endodomain were superior to other construct candidates in eliminating FR⁺ target cells in the presence of UB-TT170 in vitro. These TagCAR T cells demonstrated UB-TT170-mediated expansion and proinflammatory cytokine production in the presence of FR⁺ target cells, and repeated elimination of target cells and enhanced persistence properties with serial antigen-exposure. Cells transduced with this vector exhibited RACR-mediated expansion and improved function in the presence of rapamycin. Administration of TagCAR/RACR payload-containing lentiviral particles to PBMC-humanized NSG mice resulted in generation of TagCAR T cells in vivo, which expanded and mediated clearance of FR⁺ solid tumors with UB-TT170 <h3>Conclusions</h3> We have identified a universal TagCAR that displays robust anti-tumor activity and persistence qualities against FR⁺ target cells in vitro and in vivo with UB-TT170. These data support development of this platform as a new cellular therapy approach against solid tumors, using combinatorial targeting of tumor- and TME-associated antigens with an in vivo-generated universal TagCAR and multiple TumorTags." @default.
• W4308376056 created "2022-11-11" @default.
• W4308376056 creator A5007632857 @default.
• W4308376056 creator A5022352652 @default.
• W4308376056 creator A5046881547 @default.
• W4308376056 creator A5056267719 @default.
• W4308376056 creator A5063879916 @default.
• W4308376056 creator A5069182480 @default.
• W4308376056 creator A5070657390 @default.
• W4308376056 creator A5078488900 @default.
• W4308376056 creator A5079301432 @default.
• W4308376056 creator A5082818435 @default.
• W4308376056 date "2022-11-01" @default.
• W4308376056 modified "2023-09-25" @default.
• W4308376056 title "375 In vivo generation of universal CAR T cells that mediate durable anti-tumor immunity through combinatorial targeting with bispecific small molecule adapters" @default.
• W4308376056 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0375" @default.
• W4308376056 hasPublicationYear "2022" @default.
• W4308376056 type Work @default.
• W4308376056 citedByCount "0" @default.
• W4308376056 crossrefType "proceedings-article" @default.
• W4308376056 hasAuthorship W4308376056A5007632857 @default.
• W4308376056 hasAuthorship W4308376056A5022352652 @default.
• W4308376056 hasAuthorship W4308376056A5046881547 @default.
• W4308376056 hasAuthorship W4308376056A5056267719 @default.
• W4308376056 hasAuthorship W4308376056A5063879916 @default.
• W4308376056 hasAuthorship W4308376056A5069182480 @default.
• W4308376056 hasAuthorship W4308376056A5070657390 @default.
• W4308376056 hasAuthorship W4308376056A5078488900 @default.
• W4308376056 hasAuthorship W4308376056A5079301432 @default.
• W4308376056 hasAuthorship W4308376056A5082818435 @default.
• W4308376056 hasBestOaLocation W43083760561 @default.
• W4308376056 hasConcept C147483822 @default.
• W4308376056 hasConcept C150903083 @default.
• W4308376056 hasConcept C185592680 @default.
• W4308376056 hasConcept C202751555 @default.
• W4308376056 hasConcept C203014093 @default.
• W4308376056 hasConcept C207001950 @default.
• W4308376056 hasConcept C2776090121 @default.
• W4308376056 hasConcept C2776107976 @default.
• W4308376056 hasConcept C2776662205 @default.
• W4308376056 hasConcept C2777701055 @default.
• W4308376056 hasConcept C3020616263 @default.
• W4308376056 hasConcept C3875195 @default.
• W4308376056 hasConcept C502942594 @default.
• W4308376056 hasConcept C55493867 @default.
• W4308376056 hasConcept C86803240 @default.
• W4308376056 hasConcept C8891405 @default.
• W4308376056 hasConceptScore W4308376056C147483822 @default.
• W4308376056 hasConceptScore W4308376056C150903083 @default.
• W4308376056 hasConceptScore W4308376056C185592680 @default.
• W4308376056 hasConceptScore W4308376056C202751555 @default.
• W4308376056 hasConceptScore W4308376056C203014093 @default.
• W4308376056 hasConceptScore W4308376056C207001950 @default.
• W4308376056 hasConceptScore W4308376056C2776090121 @default.
• W4308376056 hasConceptScore W4308376056C2776107976 @default.
• W4308376056 hasConceptScore W4308376056C2776662205 @default.
• W4308376056 hasConceptScore W4308376056C2777701055 @default.
• W4308376056 hasConceptScore W4308376056C3020616263 @default.
• W4308376056 hasConceptScore W4308376056C3875195 @default.
• W4308376056 hasConceptScore W4308376056C502942594 @default.
• W4308376056 hasConceptScore W4308376056C55493867 @default.
• W4308376056 hasConceptScore W4308376056C86803240 @default.
• W4308376056 hasConceptScore W4308376056C8891405 @default.
• W4308376056 hasLocation W43083760561 @default.
• W4308376056 hasOpenAccess W4308376056 @default.
• W4308376056 hasPrimaryLocation W43083760561 @default.
• W4308376056 hasRelatedWork W1976133526 @default.
• W4308376056 hasRelatedWork W2499376085 @default.
• W4308376056 hasRelatedWork W2795515854 @default.
• W4308376056 hasRelatedWork W2917396455 @default.
• W4308376056 hasRelatedWork W2955151930 @default.
• W4308376056 hasRelatedWork W2977000124 @default.
• W4308376056 hasRelatedWork W3158325165 @default.
• W4308376056 hasRelatedWork W4284969096 @default.
• W4308376056 hasRelatedWork W4306834046 @default.
• W4308376056 hasRelatedWork W4308377693 @default.
• W4308376056 isParatext "false" @default.
• W4308376056 isRetracted "false" @default.
• W4308376056 workType "article" @default.